19:29 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient and mouse studies suggest inhibiting FBXO32 could help treat metastatic breast cancer. In patient tumor samples, FBXO32 expression was higher in invasive tumors than in non-invasive tumors. In a xenograft mouse...
18:36 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other...
22:26 , Nov 17, 2017 |  BC Extra  |  Preclinical News

FBXO32 regulates mesenchymal transition and promotes metastasis

In a paper published in Nature Communications , researchers at Johannes Gutenberg University and colleagues showed that F-box protein 32 (FBXO32) is necessary for differentiation of adherent epithelial cells into migratory mesenchymal cells, suggesting that...
07:00 , Oct 21, 2010 |  BC Innovations  |  Targets & Mechanisms

Unnerving atrophy

A team at The University of Texas Southwestern Medical Center at Dallas has shown that deletion of class IIa histone deacetylases prevents muscle atrophy after nerve damage. 1 The result suggests that inhibitors of these...